Dr. Elmets is Professor and Chair of the University of Alabama at Birmingham Department of Dermatology and Chemoprevention Program Director of UAB Comprehensive Cancer Center. Dr. Elmets received his M.D. from the University of Iowa and is board certified in Internal Medicine, Dermatology and Dermatological Immunology. He has an international reputation in skin cancer prevention, immunodermatology, and photobiology. His research has been published in critically reviewed journals. He has been of member of numerous editorial boards including Journal of the American Academy of Dermatology, JAMA Dermatology, and Journal of Investigative Dermatology. He has co-edited three books on photodermatology.
From 2003 to 2007, Dr. Krause completed her residency in Dermatology at the University Hospital Hamburg-Eppendorf in Germany. Since 2008, Dr. Krause has served as a Dermatologist and Allergist at her current institution. She is founder and coordinator of the interdisciplinary Autoinflammation Reference Center Charité (ARC²) and heads the day ward at the Department of Dermatology. Dr. Krause initiated and directed multiple clinical trials in the field of dermatology. Her main clinical and scientific areas of research are inflammatory skin diseases including urticaria and other mast cell-driven diseases, autoinflammatory syndromes and pruritus.
Graduate of Sackler School of Medicine, Tel Aviv University; Board Certification in Dermatology (1993) and Clinical and Radiation Oncology (1997). Post-doctoral research fellowship with Dr Steven Rosenberg, founder and leader of Cancer Immunotherapy, NCI, Bethesda, Md, USA, (2002-2004). Visiting professor at Ronald Levy's lab, pioneer of Monoclonal antibody-based lymphoma therapy and cancer immunotherapy, Stanford, Ca, USA. Prof. Michal Lotem is one of Israel's most experienced cancer immunotherapists, combining intensive clinical work with active leadership of scientific translational research. In the clinic, Dr Lotem participated in the pivotal clinical trials that led to FDA's approval of CTLA-4 and PD1 blockade. In parallel, Dr Lotem is conducting anti-cancer vaccination protocols, developed in her lab. Most recent is the use of engineered cancer cells with improved properties of activating immune cells. Dr Lotem's belief is that researcher clinicians should be the motivating force to guide scientific research to meet the acute needs of developing and advancing cancer cure.
Amy Paller, MS, MD is the Walter J. Hamlin Chair and Professor of Dermatology, Professor of Pediatrics, and Principal Investigator of the NIH-funded Skin Disease Research Center at Northwestern University’s Feinberg School of Medicine. She received her undergraduate and graduate degrees from Brown University and her medical degree from Stanford University. Dr. Paller completed residency training in both Pediatrics and Dermatology at Northwestern University and her postdoctoral research fellowship at the University of North Carolina. She served as Chief of Pediatric Dermatology at Lurie Children’s Hospital before becoming the Chair of Northwestern's Department of Dermatology. An author of more than 400 publications, Dr. Paller is an NIH-funded laboratory-based and clinical investigator. Her clinical interests focus on genodermatoses and pediatric cutaneous immune-mediated disorders. Her laboratory focuses on sphingolipids and lipid raft signaling; diabetic wound healing; and topically administered gene therapy using nanotechnology. She serves on the National Institutes of Health’s NIAMS Council. Dr. Paller directs the Pediatric Dermatology Clinical Trials Unit at Northwestern and has been the lead investigator on several landmark trials in pediatric skin disease. She is co-author or co-editor of leading textbooks of dermatology (Fitzpatrick’s Dermatology in General Medicine, Pediatric Dermatology, and Hurwitz’s Clinical Pediatric Dermatology) and is the Associate Editor of the Journal of Investigative Dermatology, among other journals. Dr. Paller co-chairs the Pediatric Dermatology Research Alliance (PeDRA), chairs the American Academy of Dermatology's Patient Advocacy Task Force, is Vice President of the International Society for Atopic Dermatitis, and is Vice Chair of the Dermatology Residency Review Council. She has served on the Board of the American Academy of Dermatology and American Dermatological Association, and as President and Board of Directors of the Society for Pediatric Dermatology, Society for Investigative Dermatology, Women's Dermatologic Society, International Eczema Council, and Chicago Dermatological Society. She is a Board Member of several national patient support organizations.
Dr. Maurizio Podda is Chairman of the Department of Dermatology at the Klinikum Darmstadt in Germany and teaching professor at the Goethe-University of Frankfurt. Dr. Podda has authored or coauthored more than 70 papers and 19 book chapters on the main topics of dermatologic surgery, photodermatology, skin aging, and aesthetic dermatology. He is editor of 2 books and coauthor of the major german dermatosurgery textbook. He is past-president of the German Society for Dermatologic Surgery (DGDC) and currently president of the International Society for Dermatologic surgery (ISDS).
Dr. Podda divides his time among patient care, education of medical students and medical research with a focus on surgical, aesthetic dermatology as well as the role of reactive oxygen species and antioxidants in skin aging, and photodermatology.
Pedram Gerami, MD is an Associate Professor of Dermatology, Pathology and Pediatrics at Northwestern University’s Feinberg School of Medicine and the Co-Director of melanoma research at the Northwestern Skin Cancer Institute. His interests include the utilization of clinical, histological and molecular diagnostic methods to optimize diagnostic accuracy and best predict the behavior of melanocytic neoplasms. As a clinical dermatologist, he primarily cares for patients with melanoma or atypical nevi. As a dermatopathologist, he is recognized as an international expert in the diagnosis of melanoma and is sent many second opinion cases both from within and outside of the United States. As a researcher he is focused on developing molecular based methods to improve the diagnosis and prognostication of melanocytic neoplasms.
1973-1979: Medical School, Athens University, Greece
POST GRADUATED (RESIDENCY):
1980-1981: In Internal Pathology at the Naval Hospital, Athens, Greece
1983-1985: 18 months in Dermatology-Venereology at The Hospital of Infectious Diseases, Athens
1985-1987: 18 months in Dermatology-Venereology at the Skin and Venereal Disease Hospital of Athens.
1987: Training in Lasers and Dermo-surgery, Northwestern University of Chicago.
1988: Doctor Thesis in Dermatology.
MEDICAL SOCIETY MEMBERSHIP:
- President of the Hellenic Dermatological and Venereological Society.
- President of the Council for Nail Diseases.
- Member of the European Academy of Dermatology.
- Member of the American Academy of Dermatology.
- Member of the International Society of Dermatology.
- Board Member of the European Nail Society.
- Professor of Dermatology and Venereology at the Medical School, Athens University.
- Head of the Department of Venereology and Dermatology at the General University Hospital “Attikon”, Athens (since September 2011).
15 chapters in books
Skin Appendage Disorders, Published by S. Karger AG, Basel, Switzerland
Prof. Jacob Schacther's received his MD in 1976 from the Hebrew University, Hadassah Medical Center, Jerusalem, and was recognized as certified specialist in Oncology in 1987. He is Prof. in Tel-Aviv University Medical School, and director of the Ella Institute for the Treatment and Research of Melanoma and Skin Cancer at the Sheba Medical Center in Israel. He published many original articles and chapters in books, and in peer reviewed journals on the subject of Melanoma and Tumor Immunology and presented his work in many world leadings scientific meetings. His current medical and scientific work is concentrated on adoptive immunotherapy of melanoma patients using Tumor Infiltrating Lymphocytes (TIL) Technology, and in clinical development of modern immunotherapy technologies including check-points inhibitors.
Dr. Stingl has contributed greatly to our understanding of the skin as an immune organ under physiologic and pathologic (e.g. psoriasis, atopic dermatitis, syphilis, HIV-infection) conditions. His major accomplishments include the discovery of Langerhans cells as immunocytes and of the indigenous T cell population of rodent skin. In the recent years, his research group has elucidated the mode of action of several immunomodulatory drugs. He is a member of the board of several scientific societies and organizations, advisory panels, scientific journals and committees, including honorary membership of the two leading societies of dermatological research, i.e. The Society for Investigative Dermatology and the European Society for Dermatological Research. He was recently elected a Foreign Associate of the National Academy of Medicine and holds a membership in the Austrian and German National Academy of Sciences.